GLP/GCP/GMP Expectations Explained by phase

Good Laboratory Practice (GLP), Good Clinical Practice (GCP), and Good Manufacturing Practice (GMP) are often discussed as separate systems. In reality, they represent a continuum of regulatory expectations aligned to different phases of product development and lifecycle control.

From the perspective of Quality Systems Now, understanding these frameworks by phase is essential for ensuring that data integrity, patient safety, and product quality are maintained from early research through to commercial manufacturing. Each phase introduces increasing levels of control, documentation, and validation, reflecting the growing risk profile of the product as it progresses toward human use and market release.

Early discovery and preclinical development under GLP

GLP applies primarily to non-clinical laboratory studies that support regulatory submissions. These studies are typically conducted during early discovery and preclinical development phases, where the objective is to generate reliable safety and toxicology data.

At this stage, the regulatory focus is on data integrity, traceability, and reproducibility of experimental results. GLP ensures that study design, execution, monitoring, recording, and reporting are performed under a controlled quality system.

Key expectations include clearly defined protocols, qualified personnel, validated equipment where applicable, and complete documentation of raw data. The emphasis is not on product manufacturing but on ensuring that the scientific data used to support clinical progression is credible and auditable.

From a systems perspective, GLP establishes the foundation of regulated data generation. Without this control, downstream clinical and manufacturing decisions lack a reliable scientific basis.

Transition into clinical development under GCP

Once a product enters human clinical trials, GCP becomes the governing framework. GCP applies to all phases of clinical research, from first-in-human studies through to late-stage pivotal trials.

The primary objective of GCP is the protection of trial participants and the integrity of clinical data. This introduces a shift from laboratory-based control systems to human subject research governance.

Key expectations include informed consent, ethical oversight through institutional review boards or ethics committees, investigator responsibilities, and strict protocol adherence. Clinical trial data must be recorded accurately, monitored regularly, and verified through defined quality processes.

From a regulatory compliance standpoint, GCP introduces a higher level of complexity because variability now includes human factors. Unlike GLP, where experimental conditions are controlled, clinical environments involve patient diversity, adherence variability, and clinical judgement.

At Quality Systems Now, we emphasise that GCP compliance is fundamentally about ensuring that clinical evidence is both ethically generated and scientifically reliable.

Manufacturing readiness and the introduction of GMP

GMP becomes relevant when a product moves from clinical development into manufacturing for clinical supply and eventual commercial distribution. This phase introduces the requirement for consistent, reproducible production under validated conditions.

Unlike GLP and GCP, which focus on data generation and clinical execution, GMP focuses on product quality and process control. The objective is to ensure that every batch of product meets predefined specifications and is suitable for its intended use.

Key GMP expectations include validated manufacturing processes, qualified equipment, controlled environments, documented procedures, and robust quality management systems. Each step of production must be traceable and reproducible.

This phase marks a significant shift in regulatory expectations. Variability that may be acceptable in research settings becomes unacceptable in manufacturing environments where patient safety depends on consistency.

The interface between GCP and GMP during clinical supply

During clinical trials, GMP and GCP operate in parallel. Clinical materials manufactured under GMP are used in GCP-regulated studies. This creates a critical interface between manufacturing and clinical operations.

At this stage, batch traceability, labelling control, storage conditions, and distribution systems become essential. Any deviation in manufacturing quality can directly impact clinical trial outcomes.

From a compliance perspective, alignment between GMP manufacturing controls and GCP clinical requirements is essential. Misalignment can lead to protocol deviations, invalidated data, or regulatory findings.

Quality Systems Now frequently observes that organisations underestimate the complexity of this interface, particularly in early-phase clinical supply chains.

Scale-up and process validation under GMP

As products move from clinical to commercial scale, GMP requirements intensify. This phase introduces process validation as a formal requirement to demonstrate that manufacturing processes are capable of producing consistent results at scale.

Validation activities include process validation, cleaning validation, analytical method validation, and equipment qualification. These activities are designed to confirm that the process performs reliably under routine operating conditions.

At this stage, variability must be tightly controlled. Unlike earlier phases where exploratory work is common, GMP requires defined operating ranges and documented justification for all process parameters.

From a scientific perspective, this phase represents the transition from experimental reproducibility to industrial reproducibility.

Data integrity across all phases

Data integrity is a shared expectation across GLP, GCP, and GMP, but its application differs depending on the phase.

In GLP, data integrity focuses on accurate recording of experimental results. In GCP, it extends to clinical data capture and patient safety documentation. In GMP, it includes manufacturing records, batch traceability, and quality control data.

Across all three frameworks, the principles remain consistent: data must be attributable, legible, contemporaneous, original, and accurate.

Failures in data integrity often arise from system design issues rather than intentional misconduct. Weak controls, inadequate training, or poorly designed workflows can all contribute to data reliability issues.

Risk management across the product lifecycle

Risk management becomes increasingly important as products move through GLP, GCP, and GMP phases. In early development, risk is primarily scientific. In clinical phases, it becomes patient-focused. In manufacturing, it becomes product and process-focused.

A structured risk management approach ensures that potential failures are identified and mitigated at each stage of development. This includes toxicological risk in GLP studies, patient safety risk in GCP trials, and product quality risk in GMP manufacturing.

At Quality Systems Now, we emphasise that risk management is not a standalone activity. It is a continuous process embedded across the entire product lifecycle.

Common disconnects between phases

One of the most frequent compliance challenges arises from disconnects between GLP, GCP, and GMP systems. These disconnects often occur when knowledge transfer between phases is incomplete or when assumptions are made about continuity of control.

Examples include inconsistent documentation standards between development and manufacturing, insufficient translation of clinical findings into manufacturing controls, or misalignment between analytical methods used in different phases.

These gaps can lead to regulatory delays, inspection findings, or product quality issues.